<DOC>
	<DOC>NCT02521077</DOC>
	<brief_summary>This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.</brief_summary>
	<brief_title>Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) performance status score â‰¤2; Diagnosed early stage breast cancer and scheduled to receive either adjuvant or neoadjuvant chemotherapy; Willing to receive either intravenous ascorbic acid or normal saline; Willing to use an acceptable contraceptive method for the duration of the study and for 30 days following the last dose of study drug; Negative urine or serum pregnancy test within 2 weeks prior to receipt of study drug; Willing to complete all evaluation tools; Able to give informed consent to participate in the study; and Agree to avoid any additional supplemental ascorbic acid throughout the study. Diagnosed Glucose6phosphate dehydrogenase deficiency; Renal insufficiency (Blood Urea Nitrogen &gt;30 mg/dL, or Creatinine &gt;1.5 mg/dL); Unwillingness or mental incapacity to complete selfreported questionnaires; Active smoker; and Male sex</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Fatigue</keyword>
</DOC>